Production (Stage)
Appili Therapeutics Inc.
APLI.TO
TSX
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 31.74% | 26.85% | 54.41% | 55.32% | 59.69% |
| Total Depreciation and Amortization | -4.90% | 12.36% | 28.00% | 65.57% | 117.02% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 458.67% | 68.62% | 8.46% | -30.66% | -73.33% |
| Change in Net Operating Assets | -129.24% | -15.71% | -0.42% | 246.89% | 118.95% |
| Cash from Operations | 133.12% | 80.52% | 101.58% | 92.12% | 76.36% |
| Capital Expenditure | 92.31% | 93.03% | 95.08% | 100.00% | -860.87% |
| Sale of Property, Plant, and Equipment | -- | 119.23% | 119.23% | 117.86% | 400.00% |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 92.13% | 95.56% | 97.41% | 101.84% | -881.82% |
| Total Debt Issued | 33.33% | -85.71% | -85.71% | -79.25% | -88.00% |
| Total Debt Repaid | -47.20% | -30.94% | -41.15% | -31.37% | -12.62% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 20.96% | 80.27% | 79.14% | 78.71% | -129.16% |
| Cash from Financing | 57.42% | -91.38% | -91.66% | -83.94% | -97.98% |
| Foreign Exchange rate Adjustments | -- | 316.67% | -- | -103.33% | 100.00% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 145.40% | 51.47% | 112.80% | 95.62% | 45.42% |